• Connect With Us

Study Validates Benefits of Cyberknife® Treatment

A research study conducted by the Department of Radiation Oncology at Virginia Hospital Center examined the quality of life and side effects patients experienced after CyberKnife® treatment for prostate cancer over a three-year period. Published in Radiation Oncology, the findings of the study demonstrate that CyberKnife treatment produces cancer outcomes equivalent to other treatments, while the acute urinary and sexual side effects are minimal and very well tolerated.

Virginia Hospital Center was well-positioned to conduct this research. To date, the Hospital has performed over 1,600 CyberKnife treatments (including over 300 for prostate cancer)—more than any hospital in Northern Virginia.

CyberKnife treatment is an option for early stage prostate cancer patients that delivers highly accurate doses of radiation to the prostate, minimizing unnecessary radiation and damage to surrounding healthy tissue. A non-invasive, painless radiation treatment, CyberKnife can be an alternative to open surgery and conventional radiation therapy. For prostate cancer, the CyberKnife treatment requires just five sessions, scheduled over five consecutive days. Each treatment session takes about 30 to 45 minutes.

“For a patient diagnosed with low- and intermediate-risk, organ-confined prostate cancer Virginia Hospital Center offers several options for treatment including active surveillance, surgery, external beam radiation, brachytherapy (radioactive seed implants) and CyberKnife,” says Nadim Nasr, MD, radiation oncologist. “All have comparable effectiveness in terms of PSA control, but all come with side effects and risks. We work with our patients to help them choose which treatment they feel most comfortable with, given their age, risk levels, and potential side effects.”

“Sexual, irritative, and voiding outcomes, following stereotactic body radiation therapy for prostate cancer,” Zaker Rana, Robert L. Hong, Mustafa Abugideiri, Donald McRae, George Cernica, Robert Mordkin*, Andrew B. Joel*, Gregory Bernstein* and Nadim M. Nasr | Radiation Oncology: (2015) 10:182.

*Member, Virginia Hospital Center Physician Group – Urology

The Hitt Family Center for Radiation Oncology

1701 N. George Mason Drive | Arlington, VA 22205-3698 | tel 703.558.5000
© 2018 Virginia Hospital Center All rights reserved